Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

Key Takeaways. SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021. The study used SEER 17 data, showing a steady decline in SCLC ...

A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine ...

DELPHI-304 demonstrated Imdelltra's significant survival benefit in second-line SCLC, with improved response rates and manageable safety profile, indicating a practice-changing option. Both trials ...

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a ...

It is currently being investigated in four Phase I and II studies (NCT06394414, NCT05434234, NCT06057922, NCT06241846), with a Phase III trial planned (NCT06612151) in relapsed SCLC.